Baidu
map

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance

Nash, P; Mease, PJ; Fleishaker, D; Wu, J; Coates, LC; Behrens, F; Gladman, DD; Kivitz, AJ; Wei, JC; Shirinsky, I; Menon, S; Romero, AB; Fallon, L; Hsu, MA; Wang, CS; Kanik, KS

Fleishaker, D (corresponding author), Pfizer Inc, Groton, CT 06340 USA.

LANCET RHEUMATOLOGY, 2021; 3 (1): E28

Abstract

Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. This ......

Full Text Link


Baidu
map
Baidu
map
Baidu
map